|
|
| (2 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Bivalirudin#Warnings]] |
| {{Bivalirudin}}
| |
| {{CMG}} {{AE}}{{JH}}
| |
|
| |
|
| ==Warnings and Precautions==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ====5.1 Bleeding Events====
| | [[Category: Anticoagulants]] |
| | |
| Although most bleeding associated with the use of Angiomax in PCI/PTCA occurs at the site of arterial puncture, hemorrhage can occur at any site. An unexplained fall in blood pressure or hematocrit should lead to serious consideration of a hemorrhagic event and cessation of Angiomax administration [see Adverse Reactions (6.1)]. Angiomax should be used with caution in patients with disease states associated with an increased risk of bleeding.
| |
| | |
| ====5.2 Coronary Artery Brachytherapy====
| |
| | |
| An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of Angiomax in gamma brachytherapy.
| |
| | |
| If a decision is made to use Angiomax during brachytherapy procedures, maintain meticulous catheter technique, with frequent aspiration and flushing, paying special attention to minimizing conditions of stasis within the catheter or vessels [see Adverse Reactions (6.3)].
| |
| | |
| <ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |